非小细胞肺癌(NSCLC)是一种死亡率很高的全球性肿瘤,严重威胁着人类的生命和健康。非小细胞肺癌的治疗包括手术、化疗、放疗、靶向治疗、免疫治疗等。目前,免疫疗法已显示出巨大的潜力。但一部分人并没有受益,存在原发性耐药、免疫相关...非小细胞肺癌(NSCLC)是一种死亡率很高的全球性肿瘤,严重威胁着人类的生命和健康。非小细胞肺癌的治疗包括手术、化疗、放疗、靶向治疗、免疫治疗等。目前,免疫疗法已显示出巨大的潜力。但一部分人并没有受益,存在原发性耐药、免疫相关不良事件等问题。迫切需要一种有效的标志物来筛选受益人群并判断预后。迄今为止,FDA (食品和药物管理局)唯一批准的ICI反应的生物标志物PD-L1已在临床实践中全面实施。随着进一步的研究发现PD-L1具有一定的局限性,其他相关的生物标志物仍在探索和开发中。近年来,对T淋巴细胞的研究逐渐增多,其在预后中的作用已被广泛证实。本文就非小细胞肺癌免疫治疗的现状及T淋巴细胞预后标志物的意义进行综述。Non-small cell lung cancer (NSCLC) is a global tumor with a high mortality rate, which seriously threatens human life and health. The treatment of non-small cell lung cancer includes surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc. At present, immunotherapy has shown great potential. Although immunotherapy has a good effect, some people do not benefit. There are problems such as primary drug resistance and immune-related adverse events. There is an urgent need for an effective marker to screen the beneficiary population and determine the prognosis. To date, the only FDA-approved biomarker for ICI response, PD-L1, has been fully implemented in clinical practice. As further studies have found that PD-L1 has certain limitations, other related biomarkers are still being explored and developed. In recent years, the research on T lymphocytes has gradually increased, which has a certain guiding significance for the prognosis of patients with non-small cell lung cancer. Its important role in the prognosis has been widely confirmed. This article reviews the current status of immunotherapy for non-small cell lung cancer and the significance of T lymphocyte prognostic markers.展开更多
文摘非小细胞肺癌(NSCLC)是一种死亡率很高的全球性肿瘤,严重威胁着人类的生命和健康。非小细胞肺癌的治疗包括手术、化疗、放疗、靶向治疗、免疫治疗等。目前,免疫疗法已显示出巨大的潜力。但一部分人并没有受益,存在原发性耐药、免疫相关不良事件等问题。迫切需要一种有效的标志物来筛选受益人群并判断预后。迄今为止,FDA (食品和药物管理局)唯一批准的ICI反应的生物标志物PD-L1已在临床实践中全面实施。随着进一步的研究发现PD-L1具有一定的局限性,其他相关的生物标志物仍在探索和开发中。近年来,对T淋巴细胞的研究逐渐增多,其在预后中的作用已被广泛证实。本文就非小细胞肺癌免疫治疗的现状及T淋巴细胞预后标志物的意义进行综述。Non-small cell lung cancer (NSCLC) is a global tumor with a high mortality rate, which seriously threatens human life and health. The treatment of non-small cell lung cancer includes surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc. At present, immunotherapy has shown great potential. Although immunotherapy has a good effect, some people do not benefit. There are problems such as primary drug resistance and immune-related adverse events. There is an urgent need for an effective marker to screen the beneficiary population and determine the prognosis. To date, the only FDA-approved biomarker for ICI response, PD-L1, has been fully implemented in clinical practice. As further studies have found that PD-L1 has certain limitations, other related biomarkers are still being explored and developed. In recent years, the research on T lymphocytes has gradually increased, which has a certain guiding significance for the prognosis of patients with non-small cell lung cancer. Its important role in the prognosis has been widely confirmed. This article reviews the current status of immunotherapy for non-small cell lung cancer and the significance of T lymphocyte prognostic markers.
